Literature DB >> 12531339

Experience with registered mucosal vaccines.

Guido Dietrich1, Monika Griot-Wenk, Ian C Metcalfe, Alois B Lang, Jean-François Viret.   

Abstract

Most pathogens gain access to their host through mucosal surfaces. It is therefore desirable to develop vaccination strategies that lead to mucosal immune responses. Ideally, a vaccine should be administered mucosally in order to elicit mucosal protection. Several attenuated live viral and bacterial pathogens are registered as oral vaccines for human use, including the oral polio vaccine (Sabin) as well as attenuated strains of Salmonella typhi and Vibrio cholerae. These attenuated bacterial live vaccines-S. typhi Ty21a as well as V. cholerae CVD 103-HgR-are employed as vaccines against typhoid and cholera, respectively. In this manuscript, we review the immune responses that are induced by these vaccines, with a focus on mucosal immunity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531339     DOI: 10.1016/s0264-410x(02)00579-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Oral Immunization of Mice with Live Pneumocystis murina Protects against Pneumocystis Pneumonia.

Authors:  Derrick R Samuelson; Nicholas M de la Rua; Tysheena P Charles; Sanbao Ruan; Christopher M Taylor; Eugene E Blanchard; Meng Luo; Alistair J Ramsay; Judd E Shellito; David A Welsh
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

2.  Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.

Authors:  Aziz Alami Chentoufi; Gargi Dasgupta; Anthony B Nesburn; Ilham Bettahi; Nicholas R Binder; Zareen S Choudhury; Winston D Chamberlain; Steven L Wechsler; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

3.  Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.

Authors:  Leslie W J Baillie; Ana L Rodriguez; Stephen Moore; Helen S Atkins; Chiguang Feng; James P Nataro; Marcela F Pasetti
Journal:  Vaccine       Date:  2008-09-19       Impact factor: 3.641

4.  Adjuvant potential of low dose all-trans retinoic acid during oral typhoid vaccination in Zambian men.

Authors:  M M Lisulo; M C Kapulu; R Banda; E Sinkala; V Kayamba; S Sianongo; P Kelly
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

5.  tRNA modification by GidA/MnmE is necessary for Streptococcus pyogenes virulence: a new strategy to make live attenuated strains.

Authors:  Kyu Hong Cho; Michael G Caparon
Journal:  Infect Immun       Date:  2008-04-21       Impact factor: 3.441

6.  Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations.

Authors:  Jennifer M Taylor; Melanie E Ziman; Julie Fong; Jay V Solnick; Michael Vajdy
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

7.  A novel, killed-virus nasal vaccinia virus vaccine.

Authors:  Anna U Bielinska; Alexander A Chepurnov; Jeffrey J Landers; Katarzyna W Janczak; Tatiana S Chepurnova; Gary D Luker; James R Baker
Journal:  Clin Vaccine Immunol       Date:  2007-12-05

8.  Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.

Authors:  Rhonda KuoLee; Greg Harris; J Wayne Conlan; Wangxue Chen
Journal:  Vaccine       Date:  2007-02-26       Impact factor: 3.641

9.  Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice.

Authors:  Nyasha Chin'ombe; William R Bourn; Anna-Lise Williamson; Enid G Shephard
Journal:  Virol J       Date:  2009-06-25       Impact factor: 4.099

10.  Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice.

Authors:  Sung Jae Shin; Seung Won Shin; Mi Lan Kang; Deog Yong Lee; Moon-Sik Yang; Yong-Suk Jang; Han Sang Yoo
Journal:  J Vet Sci       Date:  2007-12       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.